Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Lyell Immunopharma ( (LYEL) ) is now available.
On May 27, 2025, Lyell Immunopharma announced a reverse stock split at a 1-for-20 ratio, authorized by its stockholders during the annual meeting on May 15, 2025. Effective May 30, 2025, this move will consolidate every 20 shares into one, adjusting stock options and equity plans proportionately, with trading on a split-adjusted basis starting June 2, 2025, on Nasdaq. This action aims to streamline the company’s stock structure without altering shareholders’ proportional ownership.
The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s overall stock score reflects significant financial challenges, particularly due to the lack of revenue generation and operational losses. Technical analysis indicates a bearish trend, with the stock price below key moving averages and momentum indicators in oversold territory. Valuation metrics are also concerning, with a negative P/E ratio and no dividend yield, highlighting the need for strategic improvements to attract investor interest.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies. The company is dedicated to advancing treatments that enhance the body’s immune response to fight cancer.
Average Trading Volume: 743,391
Technical Sentiment Signal: Sell
Current Market Cap: $121.3M
For a thorough assessment of LYEL stock, go to TipRanks’ Stock Analysis page.